← Patent-cliff monitor small molecule AUGTYRO REPOTRECTINIB
Loss of exclusivity July 2036 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO
Drug detail Brand name AUGTYRO Active ingredient REPOTRECTINIB Strength 160MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval June 2024 Marketing status RX
Listed patents Patent Expires Type 11452725 July 2036 use U-3961 12310968 July 2036 use U-3755 10294242 July 2036 substance 12187739 July 2036 product RE50634 January 2035 substance, product
Regulatory exclusivity Code Expires ODE-483 June 2031 ODE* November 2030 NCE November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.